DZ2462A1 - Vaccin antigrippal. - Google Patents

Vaccin antigrippal.

Info

Publication number: DZ2462A1
Authority: DZ; Algeria
Prior art keywords: influenza vaccine; influenza; vaccine
Prior art date: 1997-04-09

Application number

DZ980072A

Other languages

English (en)

Inventor

Scharrenburg Gustaaf J M Van

Rudi Brands

Original Assignee

Duphar Int Res

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-04-09

Filing date

1998-04-06

Publication date

2003-01-18

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8228174&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DZ2462(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1998-04-06 Application filed by Duphar Int Res filed Critical Duphar Int Res

2003-01-18 Application granted granted Critical

2003-01-18 Publication of DZ2462A1 publication Critical patent/DZ2462A1/fr

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16051—Methods of production or purification of viral material
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16211—Influenzavirus B, i.e. influenza B virus
- C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Virology (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Organic Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Immunology (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Microbiology (AREA)
Genetics & Genomics (AREA)
Wood Science & Technology (AREA)
Zoology (AREA)
Mycology (AREA)
Epidemiology (AREA)
Pulmonology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Biochemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Biotechnology (AREA)
Biomedical Technology (AREA)
General Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Gastroenterology & Hepatology (AREA)
Biophysics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Peptides Or Proteins (AREA)

DZ980072A 1997-04-09 1998-04-06 Vaccin antigrippal. DZ2462A1 (fr)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
EP97201007		1997-04-09

Publications (1)

Publication Number	Publication Date
DZ2462A1 true DZ2462A1 (fr)	2003-01-18

Family

ID=8228174

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DZ980072A DZ2462A1 (fr)	1997-04-09	1998-04-06	Vaccin antigrippal.

Country Status (32)

Country	Link
US (1)	US5948410A (fr)
EP (1)	EP0870508B1 (fr)
JP (1)	JP5258127B2 (fr)
KR (1)	KR100593235B1 (fr)
CN (1)	CN1138564C (fr)
AR (1)	AR011216A1 (fr)
AT (1)	ATE197406T1 (fr)
AU (1)	AU728939B2 (fr)
BR (1)	BR9801015A (fr)
CA (1)	CA2234208C (fr)
CZ (1)	CZ297492B6 (fr)
DE (2)	DE870508T1 (fr)
DK (1)	DK0870508T3 (fr)
DZ (1)	DZ2462A1 (fr)
ES (1)	ES2129386T3 (fr)
GR (2)	GR990300017T1 (fr)
HK (1)	HK1010833A1 (fr)
HR (1)	HRP980187B1 (fr)
HU (1)	HUP9800802A3 (fr)
ID (1)	ID20399A (fr)
IL (1)	IL123961A (fr)
NO (1)	NO323349B1 (fr)
NZ (1)	NZ330131A (fr)
PL (1)	PL187982B1 (fr)
PT (1)	PT870508E (fr)
RU (1)	RU2197264C2 (fr)
SI (1)	SI0870508T1 (fr)
SK (1)	SK282614B6 (fr)
TR (1)	TR199800613A1 (fr)
TW (1)	TW570803B (fr)
UA (1)	UA42089C2 (fr)
ZA (1)	ZA982915B (fr)

Families Citing this family (100)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AR025750A1 (es) *	1999-09-24	2002-12-11	Smithkline Beecham Biolog	Vacunas
GB9923176D0 (en) *	1999-09-30	1999-12-01	Smithkline Beecham Biolog	Novel composition
CN100415769C (zh) *	2002-02-07	2008-09-03	中国科学院过程工程研究所	寡聚或多聚亚基蛋白质分离纯化的方法
ATE427990T1 (de)	2002-04-30	2009-04-15	Oncolytics Biotech Inc	Verbesserte reinigungsmethode fur viren
US20060110406A1 (en) *	2003-02-25	2006-05-25	Medimmune Vaccines, Inc.	Refrigerator-temperature stable influenza vaccine compositions
AU2004263813B8 (en)	2003-02-25	2008-09-11	Medimmune, Llc	Methods of producing influenza vaccine compositions
DE602004028736D1 (de) *	2003-06-20	2010-09-30	Microbix Biosystems Inc	Verbesserungen bei der virusproduktion
US8992939B2 (en)	2003-07-11	2015-03-31	Novavax, Inc.	Highly efficient influenza matrix (M1) proteins
US8592197B2 (en)	2003-07-11	2013-11-26	Novavax, Inc.	Functional influenza virus-like particles (VLPs)
US8506967B2 (en)	2003-07-11	2013-08-13	Novavax, Inc.	Functional influenza virus like particles (VLPs)
US8080255B2 (en)	2003-07-11	2011-12-20	Novavax Inc.	Functional influenza virus like particles (VLPs)
EP1718738A2 (fr) *	2004-02-23	2006-11-08	Crucell Holland B.V.	Procedes de purification de virus
EP1722815A1 (fr)	2004-03-09	2006-11-22	Chiron Corporation	Vaccins antigrippaux
SI1789084T1 (sl)	2004-09-09	2011-03-31	Novartis Vaccines & Diagnostic	Zmanjševanje potencialnih iatrogenih tveganj, povezanih z influenčnimi cepivi
US7901921B2 (en)	2004-10-22	2011-03-08	Oncolytics Biotech Inc.	Viral purification methods
WO2006062637A2 (fr)	2004-11-03	2006-06-15	Novartis Vaccines And Diagnostics Inc.	Vaccination antigrippale
WO2006071563A2 (fr)	2004-12-23	2006-07-06	Medimmune Vaccines, Inc.	Lignee cellulaire mdck non-oncogene destinee a propager des virus
MX2007011756A (es)	2005-03-23	2008-03-11	Glaxosmithkline Biolog Sa	Uso de un virus de la gripe y un adyuvante de emulsion de aceite en agua para inducir la respuesta mejorada de la celulas b de memoria y/o celulas t cd4.
CA2602944C (fr) *	2005-04-11	2015-08-11	Crucell Holland B.V.	Purification de virus faisant appel a une ultrafiltration
DE602006019629D1 (de) *	2005-11-01	2011-02-24	Novartis Vaccines & Diagnostic	Von zellen stammende virale impfstoffe mit geringen mengen an rest-zell-dna
US11707520B2 (en)	2005-11-03	2023-07-25	Seqirus UK Limited	Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
PL1945252T3 (pl) *	2005-11-04	2013-11-29	Seqirus Uk Ltd	Szczepionki zawierające oczyszczone antygeny powierzchniowe otrzymane z wirusów grypy hodowanych w hodowli komórkowej i skwalen jako adiuwant
WO2007052155A2 (fr)	2005-11-04	2007-05-10	Novartis Vaccines And Diagnostics Srl	Vaccins antigrippaux presentant un taux reduit d'adjuvants de type emulsion
EP1951298A1 (fr)	2005-11-04	2008-08-06	Novartis Vaccines and Diagnostics S.r.l.	Vaccins influenza avec adjuvant comprenant des agents d'induction de cytokines
DE202006021242U1 (de) *	2005-11-04	2014-01-29	Novartis Vaccines And Diagnostics S.R.L.	Emulsionen mit freiem wässrigen Phasen Tensid als Adjuvans für Spalt-Grippeimpfstoffe
CN102727885A (zh)	2005-11-04	2012-10-17	诺华疫苗和诊断有限公司	包含颗粒佐剂和免疫增强剂组合的流感疫苗
EA015271B1 (ru) *	2006-01-27	2011-06-30	Новартис Вэксинс Энд Диагностикс Гмбх & Ко Кг	Противогриппозные вакцины, содержащие гемагглютинин и белки матрикса
WO2007110776A1 (fr)	2006-03-24	2007-10-04	Novartis Vaccines And Diagnostics Gmbh & Co Kg	Stockage de vaccins antigrippaux sans refrigeration
CN101472941B (zh)	2006-03-31	2017-08-08	沃弗-威斯康星校友研究基金会	用于疫苗的高滴度重组流感病毒
PL2043682T3 (pl)	2006-07-17	2014-09-30	Glaxosmithkline Biologicals Sa	Szczepionka przeciw grypie
GB0614460D0 (en)	2006-07-20	2006-08-30	Novartis Ag	Vaccines
CA3016948A1 (fr)	2006-09-11	2008-03-20	Seqirus UK Limited	Fabrication de vaccins contre le virus grippal sans utiliser d'oeufs
CN103361319A (zh)	2006-09-15	2013-10-23	米迪缪尼有限公司	支持病毒生长到高效价的mdck细胞系和采用该细胞系的生物反应器方法
CN101553252A (zh)	2006-12-06	2009-10-07	诺华有限公司	包含来自于四株流感病毒的抗原的疫苗
WO2008109669A2 (fr) *	2007-03-05	2008-09-12	Om Pharma	Extrait bactérien pour troubles respiratoires et procédé pour sa préparation
WO2008112218A2 (fr)	2007-03-12	2008-09-18	Antigen Express, Inc.	ÉLIMINATION DE LA PROTÉINE Li IMPLIQUÉE DANS DES CONSTRUCTIONS Li-ARNi EN IMMUNOTHÉRAPIE ANTICANCÉREUSE
TW200908994A (en)	2007-04-20	2009-03-01	Glaxosmithkline Biolog Sa	Vaccine
WO2008156778A2 (fr)	2007-06-18	2008-12-24	Tokiko Watanabe	Virus mutants de protéine m2 de la grippe comme vaccins vivants atténués contre la grippe
PL2185191T3 (pl)	2007-06-27	2013-02-28	Novartis Ag	Szczepionki przeciwko grypie o małej zawartości dodatków
EP2185196B1 (fr) *	2007-08-27	2014-06-11	Longhorn Vaccines & Diagnostics, LLC	Compositions immunogènes et procédés
GB0810305D0 (en)	2008-06-05	2008-07-09	Novartis Ag	Influenza vaccination
US20110014230A1 (en)	2008-03-18	2011-01-20	Novartis Ag	preparation of influenza virus vaccine antigens
SG194372A1 (en) *	2008-09-24	2013-11-29	Medimmune Llc	Methods for cultivating cells, propagating and purifying viruses
US20110217330A1 (en) *	2008-11-05	2011-09-08	Bruno Rene Andre	Novel method
EP3173097A3 (fr)	2009-02-10	2017-07-12	Seqirus UK Limited	Vaccins contre la grippe dotés de quantités réduites de squalène
JP2012517416A (ja)	2009-02-10	2012-08-02	ノバルティスアーゲー	増加した量のｈ３抗原を含むインフルエンザワクチン
KR20110132373A (ko)	2009-02-10	2011-12-07	노파르티스 아게	유행병-연관 주에 대한 인플루엔자 백신 요법
USH2283H1 (en)	2009-04-27	2013-09-03	Novartis Ag	Vaccines for protecting against influenza
EP2401384B1 (fr)	2009-05-21	2012-10-03	Novartis AG	Génétique inverse utilisant des promoteurs pol i non endogènes
WO2010144797A2 (fr)	2009-06-12	2010-12-16	Vaccine Technologies, Incorporated	Vaccins contre la grippe avec immunogénicité accrue et leurs utilisations
CA2803282C (fr)	2009-07-06	2018-05-01	David E. Anderson	Procedes pour preparer des vesicules et formulations produites a partir de ces procedes
CN102482666B (zh)	2009-07-06	2017-02-08	变异生物技术公司	制备囊泡的方法和由其产生的制剂
EP2459722B1 (fr)	2009-07-31	2017-09-06	Seqirus UK Limited	Systemes de genetique inverse
KR20120081587A (ko)	2009-09-10	2012-07-19	노파르티스 아게	기도 질병에 대한 조합 백신
PL2491117T3 (pl)	2009-10-20	2014-05-30	Novartis Ag	Udoskonalone sposoby odzyskiwania wirusa wykorzystujące odwrotną genetykę
JP2013507990A (ja)	2009-10-26	2013-03-07	ダブリュエーアールエフ−ウィスコンシンアラムナイリサーチファウンデーション	ベロ細胞において増強された複製を有する高力価の組換えインフルエンザウイルス
US10130697B2 (en)	2010-03-23	2018-11-20	Wisconsin Alumni Research Foundation (Warf)	Vaccines comprising mutant attenuated influenza viruses
US8945904B2 (en)	2010-05-21	2015-02-03	Novartis Ag	Influenza virus reassortment
PL2575872T3 (pl)	2010-06-01	2021-02-22	Seqirus UK Limited	Zatężanie antygenów szczepionkowych grypy bez liofilizacji
PT2575873E (pt)	2010-06-01	2016-03-04	Novartis Ag	Concentração de antigénios de vacinas com liofilização
BR112013000394B8 (pt)	2010-07-06	2022-01-18	Variation Biotechnologies Inc	Composição imunogênica, uso da mesma e método para preparar a referida composição
ES2531577T3 (es)	2010-08-20	2015-03-17	Novartis Ag	Conjuntos de agujas para la administración de vacuna soluble contra la gripe
MX357319B (es)	2011-01-13	2018-07-04	Variation Biotechnologies Inc	Metodo para preparar vesiculas y formulaciones producidas de las mismas.
WO2012097346A1 (fr)	2011-01-13	2012-07-19	Variation Biotechnologies, Inc.	Compositions et méthodes de traitement d'infections virales
US20140248320A1 (en)	2011-10-20	2014-09-04	Novartis Ag	Adjuvanted influenza b virus vaccines for pediatric priming
US20140328876A1 (en)	2011-11-18	2014-11-06	Variation Biotechnologies Inc.	Synthetic derivatives of mpl and uses thereof
AU2013208693B2 (en)	2012-01-12	2017-12-07	Variation Biotechnologies Inc.	Compositions and methods for treating viral infections
EP2806894A4 (fr)	2012-01-27	2015-11-04	Variation Biotechnologies Inc	Procédés et compositions pour agents thérapeutiques
AU2013205478B9 (en)	2012-03-02	2014-11-20	Seqirus UK Limited	Influenza virus reassortment
EP2855701A1 (fr)	2012-06-04	2015-04-08	Novartis AG	Test de sécurité amélioré
GB201218195D0 (en)	2012-10-10	2012-11-21	Istituto Zooprofilattico Sperimentale Delle Venezie	Composition
KR20150110494A (ko)	2012-12-03	2015-10-02	노파르티스 아게	재배열 인플루엔자 a 바이러스
MX2015011529A (es)	2013-03-13	2016-02-05	Novartis Ag	Reordenamiento del virus de infuenza b.
KR20160030097A (ko)	2013-05-10	2016-03-16	노파르티스 아게	인플루엔자 백신에서 기면증 위험의 방지
DE202013005130U1 (de)	2013-06-05	2013-09-10	Novartis Ag	Influenza Virus Reassortierung
DE202013005100U1 (de)	2013-06-05	2013-08-26	Novartis Ag	Influenza Virus Reassortierung
EP3004332A2 (fr)	2013-06-06	2016-04-13	Novartis AG	Réassortiment du virus de la grippe
JP2016524915A (ja)	2013-07-15	2016-08-22	ウィスコンシンアルムニリサーチファンデイション	Ｍｄｃｋ、ベロ細胞又は卵内で増強された複製を有する高力価の組換えインフルエンザウイルス
RU2535153C1 (ru) *	2013-09-04	2014-12-10	Федеральное государственное унитарное предприятие "Санкт-Петербургский научно-исследовательский институт вакцин и сывороток и предприятие по производству бактерийных препаратов" Федерального медико-биологического агентства России (ФГУП СПбНИИВС ФМБА России)	Способ получения высокоочищенных вирионных концентратов
AU2014350370B2 (en) *	2013-11-15	2017-04-13	Novartis Ag	Removal of residual cell culture impurities
WO2015196150A2 (fr)	2014-06-20	2015-12-23	Wisconsin Alumni Research Foundation (Warf)	Mutations conférant une stabilité génétique à des gènes supplémentaires dans des virus de la grippe
EP2966093A1 (fr)	2014-07-07	2016-01-13	Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.	Procédé de préparation de particules de cellulose sulfatées magnétiques, particules de cellulose sulfatées magnétiques et leur utilisation
US10633422B2 (en)	2015-06-01	2020-04-28	Wisconsin Alumni Research Foundation (Warf)	Influenza virus replication by inhibiting microRNA lec7C binding to influenza viral cRNA and mRNA
RU2614127C2 (ru) *	2015-06-04	2017-03-22	Общество с ограниченной ответственностью "НТфарма"	Способ получения концентрата рекомбинантных псевдоаденовирусных частиц, экспрессирующих ген гемагглютинина вируса гриппа A/California/07/2009(H1N1)
US11013795B2 (en)	2015-06-26	2021-05-25	Seqirus UK Limited	Antigenically matched influenza vaccines
US9890363B2 (en)	2015-07-06	2018-02-13	Wisconsin Alumni Research Foundation (Warf)	Influenza virus replication for vaccine development
HUE060924T2 (hu)	2015-07-07	2023-04-28	Seqirus Uk Ltd	Influenza elleni hatásosság vizsgálata
EP3417056A1 (fr)	2016-02-19	2018-12-26	Wisconsin Alumni Research Foundation (WARF)	Réplication améliorée du virus de la grippe b pour l'élaboration de vaccin
US20200392468A1 (en)	2017-03-30	2020-12-17	Merck Sharp & Dohme Corp.	Addition of nucleases directly to cell culture to facilitate digestion and clearance of host cell nucleic acids
RU2670001C1 (ru) *	2017-12-25	2018-10-17	Федеральное государственное бюджетное учреждение науки Институт биохимии и физиологии растений и микроорганизмов Российской академии наук	Способ получения белков клеточной поверхности
AU2019207600B2 (en)	2018-01-09	2025-01-09	Theriva Biologics, Inc.	Alkaline phosphatase agents for treatment of neurodevelopmental disorders
WO2019183209A1 (fr)	2018-03-20	2019-09-26	Synthetic Biologics, Inc.	Agents au phosphatase alcaline pour le traitement de troubles dus à une exposition à des radiations
WO2019183208A1 (fr)	2018-03-20	2019-09-26	Synthetic Biologics, Inc.	Formulations de phosphatase alcaline intestinale
EP3840780A1 (fr)	2018-08-20	2021-06-30	Wisconsin Alumni Research Foundation	Vecteurs pour induire des réponses immunitaires à des épitopes non dominants dans la protéine hémagglutinine (ha)
EP3914295A2 (fr)	2019-01-23	2021-12-01	Yoshihiro Kawaoka	Mutations conférant une stabilité génétique à des gènes supplémentaires dans des virus de la grippe
CN113874496A (zh)	2019-02-08	2021-12-31	威斯康星校友研究基金会(Warf)	人源化细胞系
US11390649B2 (en)	2019-05-01	2022-07-19	Wisconsin Alumni Research Foundation (Warf)	Influenza virus replication for vaccine development
EP4022046A2 (fr)	2019-08-27	2022-07-06	Wisconsin Alumni Research Foundation (WARF)	Virus de la grippe recombinants à ha stabilisé pour réplication dans des oeufs
US20230000971A1 (en)	2019-11-18	2023-01-05	Seqirus Pty Ltd.	Method for producing reassortant influenza viruses
KR102444684B1 (ko) *	2020-04-29	2022-09-16	에스케이바이오사이언스(주)	일회용 배양 공정 시스템을 이용한 인플루엔자 바이러스 생산 방법

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CH589453A5 (fr) *	1974-01-14	1977-07-15	Sandoz Ag
US4500513A (en) *	1979-05-15	1985-02-19	Miles Laboratories, Inc.	Influenza vaccine production in liquid cell culture
US4317811A (en) *	1980-09-11	1982-03-02	Merck & Co., Inc.	Herpes simplex type 1 subunit vaccine
DE3237313A1 (de) *	1982-10-08	1984-04-12	Werner Heese	Verfahren zur gewinnung und reinigung antigenhaltiger loesungen, insbesondere fuer influenza-viren, aus antigenhaltiger allantoisfluessigkeit
US4783411A (en) *	1984-10-22	1988-11-08	Janis Gabliks	Influenza-A virus vaccine from fish cell cultures
US5173418A (en) *	1985-05-10	1992-12-22	Benzon Pharma, A/S	Production in Escherichia coli of extracellular Serratia spp. hydrolases
US5006472A (en) *	1988-06-03	1991-04-09	Miles Inc.	Enzymatic purification process
DK0408742T3 (da) *	1989-02-07	1995-03-20	Bio Technology General Corp	Fremgangsmåde til fremstilling og rensning af hepatitis B vaccine
DE69024392T2 (de) *	1989-03-29	1996-07-25	Univ New York	Verfahren zur Reinigungbvon Aussenmembran-Protein von Haemophilus influenzae
DZ1706A1 (fr) *	1992-08-07	2002-02-17	Merck & Co Inc	Vaccin contre le virus de l'hepatite a.
HRP950097A2 (en) *	1994-03-08	1997-06-30	Merck & Co Inc	Hepatitis a virus culture process
ES2323490T3 (es) *	1994-11-10	2009-07-17	Baxter Healthcare Sa	Procedimiento de produccion de agentes biologicos en un medio de cultivo sin proteinas.
US5681746A (en) *	1994-12-30	1997-10-28	Chiron Viagene, Inc.	Retroviral delivery of full length factor VIII
CA2228128C (fr) *	1995-08-01	2011-03-29	Pasteur Merieux Serums & Vaccins	Procede de production industrielle d'un vaccin contre l'encephalite japonaise et vaccin obtenu
EP0863704A4 (fr) *	1995-09-28	2003-09-10	Univ Pittsburgh	Stimulation de reponses immunes cellulaires par une imunisation genique ciblee utilisant un agent particulaire

1998
- 1998-04-01 TW TW087104913A patent/TW570803B/zh not_active IP Right Cessation
- 1998-04-02 TR TR1998/00613A patent/TR199800613A1/xx unknown
- 1998-04-02 PT PT98201056T patent/PT870508E/pt unknown
- 1998-04-02 AT AT98201056T patent/ATE197406T1/de active
- 1998-04-02 EP EP98201056A patent/EP0870508B1/fr not_active Revoked
- 1998-04-02 SI SI9830010T patent/SI0870508T1/xx unknown
- 1998-04-02 ES ES98201056T patent/ES2129386T3/es not_active Expired - Lifetime
- 1998-04-02 DE DE0870508T patent/DE870508T1/de active Pending
- 1998-04-02 DK DK98201056T patent/DK0870508T3/da active
- 1998-04-02 DE DE69800383T patent/DE69800383T2/de not_active Expired - Lifetime
- 1998-04-06 IL IL12396198A patent/IL123961A/xx not_active IP Right Cessation
- 1998-04-06 NO NO981557A patent/NO323349B1/no not_active IP Right Cessation
- 1998-04-06 KR KR1019980012018A patent/KR100593235B1/ko not_active IP Right Cessation
- 1998-04-06 AU AU60659/98A patent/AU728939B2/en not_active Expired
- 1998-04-06 CN CNB981080863A patent/CN1138564C/zh not_active Expired - Lifetime
- 1998-04-06 PL PL98325722A patent/PL187982B1/pl unknown
- 1998-04-06 HU HU9800802A patent/HUP9800802A3/hu not_active Application Discontinuation
- 1998-04-06 SK SK445-98A patent/SK282614B6/sk not_active IP Right Cessation
- 1998-04-06 NZ NZ330131A patent/NZ330131A/en not_active IP Right Cessation
- 1998-04-06 BR BR9801015-8A patent/BR9801015A/pt not_active Application Discontinuation
- 1998-04-06 ZA ZA982915A patent/ZA982915B/xx unknown
- 1998-04-06 ID IDP980519A patent/ID20399A/id unknown
- 1998-04-06 HR HR980187A patent/HRP980187B1/xx not_active IP Right Cessation
- 1998-04-06 CZ CZ0105098A patent/CZ297492B6/cs unknown
- 1998-04-06 US US09/055,321 patent/US5948410A/en not_active Expired - Lifetime
- 1998-04-06 CA CA002234208A patent/CA2234208C/fr not_active Expired - Lifetime
- 1998-04-06 DZ DZ980072A patent/DZ2462A1/fr active
- 1998-04-06 RU RU98106860/13A patent/RU2197264C2/ru active
- 1998-04-07 JP JP11010198A patent/JP5258127B2/ja not_active Expired - Lifetime
- 1998-04-08 UA UA98041787A patent/UA42089C2/uk unknown
- 1998-04-08 AR ARP980101611A patent/AR011216A1/es not_active Application Discontinuation
- 1998-11-17 HK HK98112068A patent/HK1010833A1/xx not_active IP Right Cessation
1999
- 1999-01-01 GR GR990300017T patent/GR990300017T1/el unknown
2000
- 2000-11-09 GR GR20000402476T patent/GR3034798T3/el not_active IP Right Cessation

Also Published As

Publication number	Publication date
SK44598A3 (en)	1998-11-04
RU2197264C2 (ru)	2003-01-27
ATE197406T1 (de)	2000-11-11
TW570803B (en)	2004-01-11
ID20399A (id)	1998-12-10
NO323349B1 (no)	2007-04-02
NO981557L (no)	1998-10-12
US5948410A (en)	1999-09-07
HUP9800802A2 (hu)	1999-04-28
HU9800802D0 (en)	1998-05-28
ZA982915B (en)	1999-01-21
BR9801015A (pt)	2000-01-11
JP5258127B2 (ja)	2013-08-07
JPH1121253A (ja)	1999-01-26
CZ297492B6 (cs)	2007-01-03
CZ105098A3 (cs)	1998-10-14
DK0870508T3 (da)	2000-11-20
HRP980187A2 (en)	1999-04-30
CA2234208A1 (fr)	1998-10-09
MX9802766A (es)	1998-12-31
DE69800383T2 (de)	2001-08-16
PL325722A1 (en)	1998-10-12
NO981557D0 (no)	1998-04-06
PT870508E (pt)	2001-04-30
HUP9800802A3 (en)	2003-08-28
SI0870508T1 (en)	2001-02-28
DE69800383D1 (de)	2000-12-14
AR011216A1 (es)	2000-08-02
TR199800613A1 (xx)	1998-10-21
KR19980081114A (ko)	1998-11-25
AU6065998A (en)	1998-10-15
CN1138564C (zh)	2004-02-18
CA2234208C (fr)	2003-06-10
PL187982B1 (pl)	2004-11-30
DE870508T1 (de)	1999-08-19
AU728939B2 (en)	2001-01-18
GR990300017T1 (en)	1999-06-30
UA42089C2 (uk)	2001-10-15
NZ330131A (en)	1999-10-28
CN1196956A (zh)	1998-10-28
ES2129386T3 (es)	2001-01-01
HRP980187B1 (en)	2001-04-30
SK282614B6 (sk)	2002-10-08
IL123961A (en)	2000-07-16
KR100593235B1 (ko)	2007-12-04
EP0870508B1 (fr)	2000-11-08
ES2129386T1 (es)	1999-06-16
HK1010833A1 (en)	1999-07-02
EP0870508A1 (fr)	1998-10-14
GR3034798T3 (en)	2001-02-28

Publication	Publication Date	Title
DZ2462A1 (fr)	2003-01-18	Vaccin antigrippal.
NO20003302L (no)	2000-08-18	Vaksine
NO996133D0 (no)	1999-12-10	Olje-i-vann-vaksinesammensetninger
NO20014322D0 (no)	2001-09-05	Vaksine
NO20006191D0 (no)	2000-12-06	Vaksine
DZ3219A1 (fr)	2001-02-22	Vaccin
DE60002650D1 (de)	2003-06-18	Öladjuvierter Impfstoff
DZ2283A1 (fr)	2002-12-25	Composition de vaccin.
NO20005599L (no)	2001-01-08	Vaksine
FR2715304B1 (fr)	1996-04-26	Vaccin anti-allergique.
IS6184A (is)	2001-11-29	Bóluefni gegn ISA veiru
BR9807299B1 (pt)	2009-01-13	vacina contra bursite infecciosa.
ATE431415T1 (de)	2009-05-15	Hiv impfstoff
BR1100968A (pt)	2002-04-09	Formulação de vacina de subunidade
ITMI981384A0 (it)	1998-06-17	Vaccino per hiv
ITMI992410A0 (it)	1999-11-18	Vaccino per hiv
BR9704150B1 (pt)	2011-04-05	vacina contra carrapatos.